Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record.

Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension

McLaughlin, Vallerie V., Gaine, Sean P., Barst, Robyn J., Oudiz, Ronald J., Bourge, Robert C., Frost, Adaani, Robbins, Ivan M., Tapson, Victor F., McGoon, Michael D., Badesch, David B., Sigman, Jeff, Roscigno, Robert, Blackburn, Shelmer D., Arneson, Carl, Rubin, Lewis J., Rich, Stuart · 2003 · Journal of Cardiovascular Pharmacology

Abstract

Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous infusion and is associated with adverse effects. The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmonary hypertension. Ten tertiary care academic institutions with pulmonary hypertension programs participated in these pilot trials. In the first trial, intravenous epoprostenol and intravenous treprostinil were compared. In the second trial, intravenous treprostinil and subcutaneous treprostinil were compared. In the third trial, subcutaneous treprostinil was compared with placebo infusion during an 8-week period. Intravenous epoprostenol and intravenous treprostinil resulted in a similar reduction in pulmonary vascular resistance acutely (22% and 20%, respectively). Intravenous treprostinil and subcutaneous treprostinil also demonstrated comparable short-term decrease in pulmonary vascular resistance (23% and 28%, respectively). The placebo-controlled 8-week trial demonstrated a mean improvement of 37 +/- 17 m as measured by the 6-minute walk distance in patients receiving treprostinil compared with a 6 +/- 28 m reduction in those receiving placebo. There were trends toward an improvement in cardiac index and pulmonary vascular resistance index in the treprostinil group. Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term. Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00005344-200302000-00019

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 232

Metadata

Authors
McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., Sigman, J., Roscigno, R., Blackburn, S. D., Arneson, C., Rubin, L. J., & Rich, S.
Venue
Journal of Cardiovascular Pharmacology
Published
2003-02
Volume
41
Issue
2
Pages
293-299
ISSN
0160-2446 (ISSN-L)
OpenAlex
W2008067043
Cited by
232
References
0
FWCI
14.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. https://app.cochat.ai/papers/10.1097/00005344-200302000-00019
The paper
McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., Sigman, J., Roscigno, R., Blackburn, S. D., Arneson, C., Rubin, L. J., & Rich, S. (2003). Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-200302000-00019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.